BMA House caught in the blast
S Murray - CMAJ, 2005 - Can Med Assoc
NEWS more. What makes me anxious is the [media] coverage about trastuzumab, which
makes it sound as if you're going to die if you don't get it right away.” The drug is also …
makes it sound as if you're going to die if you don't get it right away.” The drug is also …
[CITATION][C] Reply to Clinical practice patterns and cost effectiveness of human epidermal growth receptor 2 testing strategies in breast cancer patients
KA Phillips, EB Elkin, JS Haas - Cancer, 2010 - Wiley Online Library
In their recently published article, Phillips et al state that there is little information about HER-
2 testing in clinical practice and suggest that testing is not being done in many cases. 1 …
2 testing in clinical practice and suggest that testing is not being done in many cases. 1 …
HER-2 and fluorescent in situ hybridization to evaluate breast cancer
T Tanvetyanon - JAMA, 2004 - jamanetwork.com
To the Editor: Dr Yaziji and colleagues1 compared immunohistochemistry (IHC) and
fluorescence in situ hybridization (FISH) tests for overexpression of human epidermal growth …
fluorescence in situ hybridization (FISH) tests for overexpression of human epidermal growth …
[CITATION][C] Clinical practice patterns and cost‐effectiveness of human epidermal growth receptor 2 testing strategies in breast cancer patients
P Fitzgibbons, MK Washington, D Murphy - Cancer, 2010 - Wiley Online Library
In their recently published article, Phillips et al state that there is little information about HER-
2 testing in clinical practice and suggest that testing is not being done in many cases. 1 …
2 testing in clinical practice and suggest that testing is not being done in many cases. 1 …
[CITATION][C] HER-2 Testing in Breast Cancer—Reply.
H Yaziji, TS Barry, AM Gown - JAMA: Journal of the …, 2004 - search.ebscohost.com
RESEARCH LETTER Page 1 FDA-approved IHC tests.Also, if an FDA IHC kit is modified from
the specified protocol, including a customized interpretation that subtracts normal tissue …
the specified protocol, including a customized interpretation that subtracts normal tissue …
Patient demand and politics push Herceptin forward
W Kondro, B Sibbald - Cmaj, 2005 - Can Med Assoc
NEWS more. What makes me anxious is the [media] coverage about trastuzumab, which
makes it sound as if you're going to die if you don't get it right away.” The drug is also …
makes it sound as if you're going to die if you don't get it right away.” The drug is also …
[HTML][HTML] New Breast Cancer Cure?
R Schilling - 2016 - askdrray.com
According to the popular press there is a new breast cancer cure. But we have to be careful
with general statements like this. First of all, only 20% of breast cancers are HER2 positive …
with general statements like this. First of all, only 20% of breast cancers are HER2 positive …
Abstract PS7-78: Trends in BRCA testing among patients diagnosed with breast cancer-a retrospective analysis of a United States commercial claims database from …
Background The use of BRCA testing to guide the course of breast cancer treatment has
evolved in the last 5 years; however, little is known about the use of BRCA testing in a real …
evolved in the last 5 years; however, little is known about the use of BRCA testing in a real …
HER-2 and Fluorescent In Situ Hybridization to Evaluate Breast Cancer—Reply
H Yaziji - JAMA, 2004 - jamanetwork.com
To the Editor: Dr Yaziji and colleagues1 compared immunohistochemistry (IHC) and
fluorescence in situ hybridization (FISH) tests for overexpression of human epidermal growth …
fluorescence in situ hybridization (FISH) tests for overexpression of human epidermal growth …
High-quality HER-2 testing: setting a standard for oncologic biomarker assessment
EL Wiley, LK Diaz - Jama, 2004 - jamanetwork.com
IN THIS ISSUE OF THE JOURNAL, YAZIJI AND COLLEAGUES1 report the results from an
elegant study that should help to inform the ongoing debate over a controversial topic …
elegant study that should help to inform the ongoing debate over a controversial topic …
